Unavailable
Unavailable
Save time and jump to the most important pieces.
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Marijn Dekkers, Ph.D. and Ruth Fattori to its Board of Directors. Both Dr. Dekkers and Ms. Fattori have agreed to continue to serve on the Board of Directors of the combined company subsequent to the closing of the previously announced business combination between Quantum-Si and HighCape Capital Acquisition Corp (NASDAQ:CAPA). "We are positioning Quantum-Si to have the best chance of delivering on the promise of next-generation proteomics by continuing to enhance our leadership team and board of directors, including the addition of Dr. Marijn Dekkers, former
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Michael Mina, M.D., Ph.D., Assistant Professor of Epidemiology, Immunology, Infectious Diseases and Pathology at the Harvard T.H. Chan School of Public Health and Harvard Medical School, as Chief Medical Advisor for the company. "As we create the next generation of protein sequencing and proteomics to transform how we study and diagnose disease, moving from the analog to the digital world and allowing a level of sensitivity, precision and understanding never before possible, Dr. Mina's expertise will be invaluable in guiding Quantum-Si's application efforts,
8-K - Quantum-Si Inc (0001816431) (Filer)
S-1 - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
RALEIGH, NC / ACCESSWIRE / July 1, 2024 / Issuer Direct Corporation (NYSE:ISDR), an industry-leading communications company, today announced it has appointed Wes Pollard and Joe Staples as new independent members of its Board of Directors."We are excited to welcome Wes and Joe to the Issuer Direct Board of Directors," said CEO Brian Balbirnie. "We believe their respective skillsets are an ideal fit for us as we pursue our strategic vision to be a leading provider of media and communications software to the PR (Public Relations) and IR (Investor Relations) industry. We are confident they will be valuable additions to our company as we continue to optimize our business and work to maximize val
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a life science tools company commercializing a unique protein sequencing platform, announced today that they have expanded their Platinum early access program to ten sites, with participation from leading academic centers and key industry partners. The early access program introduces the Platinum single molecule sequencing system to key opinion leaders across the globe, for both expansion and development of applications and workflows. "The Company is experiencing tremendous momentum and demand for participation in our early access program to analyze previously unapproachable levels of biological understanding of t
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30, 2021. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, September 29, at 1:20 – 1:50 pm EDT. Please visit the Investor Relations section of the Quantum-Si website here to view the Company's most recent corporate presentation. About Quantum-Si Incorporated Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focus
SC 13D - Quantum-Si Inc (0001816431) (Subject)
SC 13D - Quantum-Si Inc (0001816431) (Subject)
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
Quantum-Si Solidifies Financial Strength and Continues Systematic Commercialization Strategy Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced financial results for the quarter ended June 30, 2021 and provided a business update. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Quantum-Si's Chief Financial Officer, will host a call today at 4:30 pm EDT to review the Company's results. Recent Highlights: Completed the business combination with HighCape Capital Acquisition Corp. ("HighCape"), adding over $511 million in cash to the balance sheet. Successfull
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has rescheduled its conference call to report second quarter 2021 financial results to August 16, 2021, after market close. John Stark, Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET on August 16, 2021, to discuss second quarter 2021 financial results and provide a business update. The conference call will be broadcast live in listen-only mode via a webcast on Quantum-Si's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on y